Literature DB >> 10571595

Effects of current and former cigarette smoking on the clinical course of Crohn's disease.

J Cosnes1, F Carbonnel, F Carrat, L Beaugerie, S Cattan, J Gendre.   

Abstract

BACKGROUND: Cigarette smoking is associated with a more severe course of Crohn's disease, but individual factors determining this effect are poorly known and it is not clear whether smoking cessation is associated with an improvement in the disease activity. AIM: To assess the factors determining the harmful effect of smoking in individuals with Crohn's disease.
METHODS: A total of 622 consecutive patients with Crohn's disease and Crohn's disease activity index <200 were enrolled in a prospective 12-18 month cohort study. Patients were classified as current smokers, former smokers, or non-smokers. Alcohol consumption, oral contraceptive use, body mass index, and blood lipid levels were also recorded. The main outcome measure was the rate of flare-up.
RESULTS: A total of 139 current smokers (46%) developed a flare-up, vs. 79 non-smokers (30%) and 13 former smokers (23%). The relative risk of flare-up adjusted for confounding factors was 1.35 (1.03-1.76) in current smokers. This risk was increased in patients with previously inactive disease and in those who had no colonic lesions. It became significant above a threshold of 15 cigarettes per day. Former smokers behaved like non-smokers. Obesity, dyslipidaemia, and alcohol consumption had no significant effect.
CONCLUSIONS: Current smoking, particularly heavy smoking, markedly increases the risk of flare-up in Crohn's disease. Former smokers have a risk similar to that of non-smokers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571595     DOI: 10.1046/j.1365-2036.1999.00630.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  57 in total

1.  Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis.

Authors:  H S Odes; A Fich; S Reif; A Halak; A Lavy; D Keter; R Eliakim; J Paz; E Broide; Y Niv; Y Ron; Y Villa; N Arber; T Gilat
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

Review 2.  Management of Crohn's disease in smokers: is an alternative approach necessary?

Authors:  Pilar Nos; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2011-08-21       Impact factor: 5.742

3.  Assessment of variables associated with smoking cessation in Crohn's disease.

Authors:  Yvette Leung; Gil G Kaplan; Kevin P Rioux; James Hubbard; Sarah Kamhawi; Lidia Stasiak; Russell D Cohen; Shane M Devlin; Remo Panaccione; Stephen B Hanauer; David T Rubin
Journal:  Dig Dis Sci       Date:  2012-02-07       Impact factor: 3.199

Review 4.  Smoking in inflammatory bowel diseases: good, bad or ugly?

Authors:  Peter Laszlo Lakatos; Tamas Szamosi; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 5.  Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature.

Authors:  Natasha-A Koloski; Laurel Bret; Graham Radford-Smith
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

6.  Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ramnik J Xavier
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 7.  Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

8.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

9.  Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.

Authors:  D G Forcione; M J Rosen; J B Kisiel; B E Sands
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

10.  Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease.

Authors:  Marian C Aldhous; Colin L Noble; Jack Satsangi
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.